Transdermal Nicotine Treatment and Progression of Early Parkinson's Disease

NEJM Evid. 2023 Sep;2(9):EVIDoa2200311. doi: 10.1056/EVIDoa2200311. Epub 2023 Aug 22.

Abstract

Nicotine Treatment and Parkinson's DiseaseIn this randomized, controlled trial, patients with Parkinson's disease not on dopaminergic therapy were randomly assigned to receive transdermal nicotine or placebo. After 1 year, there was no difference in the change in Total Unified Parkinson's Disease Rating Scale score between groups.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Administration, Cutaneous
  • Antiparkinson Agents
  • Dopamine / therapeutic use
  • Humans
  • Nicotine
  • Parkinson Disease* / drug therapy

Substances

  • Antiparkinson Agents
  • Nicotine
  • Dopamine